Heterogeneity in lung cancer
VML de Sousa, L Carvalho - Pathobiology, 2018 - karger.com
Lung cancer diagnosis is a challenge since it is also one of the most frequently diagnosed
cancers. Diagnostic challenges are deeply related to the development of personalized …
cancers. Diagnostic challenges are deeply related to the development of personalized …
Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in …
H Linardou, IJ Dahabreh, D Kanaloupiti… - The lancet …, 2008 - thelancet.com
Background Somatic mutations of the k-RAS oncogene have been assessed as a
mechanism of de-novo resistance to epidermal growth factor receptor (EGFR) tyrosine …
mechanism of de-novo resistance to epidermal growth factor receptor (EGFR) tyrosine …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
[HTML][HTML] LAG-3 protein expression in non–small cell lung cancer and its relationship with PD-1/PD-L1 and tumor-infiltrating lymphocytes
Introduction Immunotherapy targeting the programmed death 1 (PD-1)/programmed death
ligand 1 (PD-L1) checkpoint has shown promising efficacy in patients with NSCLC …
ligand 1 (PD-L1) checkpoint has shown promising efficacy in patients with NSCLC …
Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an …
DM Jackman, VA Miller, LA Cioffredi, BY Yeap… - Clinical Cancer …, 2009 - AACR
Purpose: The impact of epidermal growth factor receptor (EGFR) and KRAS genotypes on
outcomes with erlotinib or gefitinib therapy continues to be debated. This study combines …
outcomes with erlotinib or gefitinib therapy continues to be debated. This study combines …
KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies
Epidemiologic studies have evaluated the association between KRAS mutations and
resistance to the treatment of epidermal growth factor receptor (EGFR) tyrosine-kinase …
resistance to the treatment of epidermal growth factor receptor (EGFR) tyrosine-kinase …
Prospective Molecular Marker Analyses of EGFR and KRAS From a Randomized, Placebo-Controlled Study of Erlotinib Maintenance Therapy in Advanced Non …
W Brugger, N Triller, M Blasinska-Morawiec… - Journal of Clinical …, 2011 - ascopubs.org
Purpose The phase III, randomized, placebo-controlled Sequential Tarceva in Unresectable
NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended …
NSCLC (SATURN; BO18192) study found that erlotinib maintenance therapy extended …
Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase …
B Wacker, T Nagrani, J Weinberg, K Witt, G Clark… - Clinical Cancer …, 2007 - AACR
Purpose: Data from two large phase III studies were analyzed to characterize the correlation
between the occurrence of rash during treatment with the epidermal growth factor receptor …
between the occurrence of rash during treatment with the epidermal growth factor receptor …
[PDF][PDF] First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial
C Gridelli, F Ciardiello, C Gallo, R Feld, C Butts… - J Clin Oncol, 2012 - academia.edu
Purpose Erlotinib prolonged survival of unselected patients with advanced non–small-cell
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
lung cancer (NSCLC) who were not eligible for further chemotherapy, and two phase II …
The ERBB3 receptor in cancer and cancer gene therapy
G Sithanandam, LM Anderson - Cancer gene therapy, 2008 - nature.com
ERBB3, a member of the epidermal growth factor receptor (EGFR) family, is unique in that its
tyrosine kinase domain is functionally defective. It is activated by neuregulins, by other …
tyrosine kinase domain is functionally defective. It is activated by neuregulins, by other …